Olverembatinib Induces Responses in Patients With Ponatinib-Resistant, T315I-Mutant CML, and Ph-Positive ALLDecember 13th 2022
An early study showed that encouraging responses were elicited with olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Single Agent Belantamab Mafodotin Shows Deep and Durable Responses in Final Analysis of RRMM StudyDecember 12th 2022
In a final analysis of the DREAMM-2 study, results showed the rapid and durable responses of belantamab mafodotin continued in patients with relapsed/refractory multiple myeloma despite ocular toxicities.
Acalabrutinib Appears to Have Quicker Time to Next Therapy Than Ibrutinib in Patients With CLLDecember 12th 2022
Patients with chronic lymphocytic leukemia on frontline acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, compared to those on ibrutinib, according to real-world study data.
Belantamb Mafodotin Shows PFS Benefit and Tolerable Safety in R/R Multiple MyelomaDecember 12th 2022
Compared with standard of care regimens for triple-class exposed, relapsed or refractory multiple myeloma, belantamb mafodotin with pomalidomide and dexamethasone extended progression-free survival without sacrificing safety.
Crovalimab Treatment in the COMMODORE Trial Meets Coprimary End PointsDecember 11th 2022
COMMODORE study results are positive for its two primary end points of stable hemolysis control and transfusion avoidance in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab.
Lenalidomide/ Rituximab Extends 5-Year PFS on R/R Indolent Non-Hodgkin LymphomaDecember 11th 2022
Five-year follow up results from the phase 3 AUGMENT trial show that lenalidomide plus rituximab produced enhanced progression-free survival in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
Intensive Remission Induction Chemotherapy Prior to alloHCT Does Not Show Survival Advantage in R/R AMLDecember 10th 2022
Comparing intensive remission induction chemotherapy prior to allogeneic hematopoietic cell transplantation to watchful waiting followed by sequential conditioning did not show superior results.
Obintutuzumab Given Prior to Fixed-Duration Glofitamab Shows Durable Responses in R/R MCLDecember 10th 2022
Pretreatment with Obinutuzumab aids fixed-duration regimen of glofitamab in high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.
Responses to Cilta-Cel Durable for Nearly 2 Years Across Several R/R Multiple Myeloma SubgroupsDecember 15th 2021
Updated findings from the CARTITUDE-1 trial presented at the 2021 ASH Annual Meeting and Exposition show that the use of a CAR T-cell therapy resulted in durable responses that lasted at nearly 2 years of follow-up across most subgroups with relapsed/refractory multiple myeloma.